CN1238780A - Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease - Google Patents

Abstract

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

Description

Serine protease, the particularly inhibitor of hepatitis C virus NS proteolytic enzyme

The present invention relates to a kind of new as proteinase inhibitor in particular as serpin with as the compound of hepatitis C NS3 proteinase inhibitor.They play a role by the life cycle of disturbing hepatitis C virus and also are used as antiviral agent.

The present invention also relates to comprise the pharmaceutical composition of these compounds.The compounds of this invention and pharmaceutical composition are specially adapted to suppress HCV NS3 protease activity and therefore can rely on the therapeutical agent of serine protease virus of proliferation as hepatitis C virus and other effectively.The present invention also relates to utilize The compounds of this invention and related compound thereof to come the arrestin enzyme to comprise the method for hepatitis C virus NS proteolytic enzyme and other serine protease.

The infection that is caused by hepatitis C virus (" HCV ") is to cause the human medical problem of paying close attention to.It is believed that HCV is the cause agent of most of non-first, non-hepatitis B, estimate that human serum carrying rate (seroprevalence) is the 1%[Purcell of sum, R.H., " hepatitis C virus: traditional view and existing notion " FEMS microorganism summary 14,181-192 page or leaf (1994); Van der Poel, C.L., " hepatitis C. prevailing disease, the infection of hepatitis C and prevention.The present research of blood and blood transfusion, H.W.Reesink, Ed., (Basel:Karger), 137-163 page or leaf (1994)].Only the U.S. may just have four million peoples be subjected to infecting [Alter, M.J. and Mast, E.E., " viral hepatitis is at the epidemiology of the U.S., Gastroenterol.Clin.North Am.23, pp.437-455 (1994)].

When contacting HCV for the first time, only there is about 20% sufferer to develop into acute hepatitis, other people then eliminates automatically and infects.Yet in most of the cases, virus causes the chronic infection [Iwarson, S. " natural process of chronic hepatitis " FEMS microbiology summary 14,201-204 page or leaf (1994)] in sustainable ten years.This causes recurrent and hepatitis that run down usually, and therefore cause more serious disease such as liver cirrhosis and hepatocellular carcinoma usually [Kew, M.C., " hepatitis C and liver cell tumor ", the FEMS microorganism summarizes 14,211-220 page or leaf (1994); Saito, I. waits people's " relation of infection with hepatitis C virus and liver cell tumor development " institute of NAS newspaper 87,6547-6549 page or leaf (1990)].Unfortunately, there is not extensively effective methods of treatment to weaken the process of chronic hcv.

The HCV genome encoding have 3010-3033 amino acid whose polyprotein [Choo, Q.-L. wait people's " gene organization of hepatitis C virus and diversity ", institute of NAS newspaper 88,2451-2455 page or leaf (1991); Kato, people such as N. " from the genomic molecular cloning of Japanese hepatitis A, B patient's viruses of human hepatitis C ", institute of NAS newspaper 87,9524-9528 page or leaf (1990); Takamizawa, people such as A. " by genomic structure of the isolated hepatitis C of human carrier and tissue ", viral magazine, 65,1105-1113 page or leaf (1991)].Infer that the non-structure of HCV (NS) albumen provides virus replication essential catalysis mechanism.NS albumen makes the polyprotein fracture produce [Bartenschlager by proteolysis, R. wait people's " Nonstructural Protein 3 coding of hepatitis C virus be used to rupture the serine-type proteolytic enzyme that NS3/4 is connected with NS4/5 ", the virus magazine, 67,3835-3844 page or leaf (1993); Grakoui, people such as A. " feature of the serine protease of hepatitis C virus coding: the mensuration of proteolytic enzyme-dependence polyprotein broken site ", viral magazine, 67,2832-2843 page or leaf (1993); Grakoui, people such as A., the expression and the evaluation of hepatitis C virus polyprotein cleavage product ", viral magazine, 67,1385-1395 page or leaf (1993); Tomei, people such as L., " Ns3 is the serine protease that is used to process the hepatitis C virus polyprotein ", viral magazine, 67,4017-4026 page or leaf (1993)].

HCV NS albumen 3 (NS3) comprises serine protease, and it helps most of viral enzyme is disposed, and thinks that therefore virus replication is essential with infection.Known, the sudden change of yellow fever virus NS3 proteolytic enzyme has reduced viral infectivity [Chambers, T.J. wait the people, " is to be responsible for the evidence of serine protease of the site-specific fracture of viral polyprotein from the N-end region of the Nonstructural Protein Ns3 of yellow fever virus ", institute of NAS newspaper 87,8898-8902 page or leaf (1990)].Initial 181 amino acid (the 1027-1207 residue of albumen polyprotein) of NS3 have shown the serine protease district that contains NS3, it disposes [people such as C.Lin to all four downstream portion of HCV proteolytic enzyme, " hepatitis C Ns3 serine protease: trans-fracture demand and processing dynamics are learned ", the virus magazine, 68, people such as 8147-8157 (1994)].

HCV NS3 Serine and relevant cofactor NS4A thereof help all proteolytic enzyme is disposed, and think that therefore virus is auxiliary essential.This disposal process is that the disposal process of carrying out with human immunodeficiency virus's aspartyl proteolytic enzyme is similar, this process also relates to viral enzyme and disposes the hiv protease inhibitor, this proteinase inhibitor suppresses the viral protein disposal process, it is human potent antiviral agent, this shows, this stage of viral interference life cycle produces effective therapeutical agent.So it is the attractive target of drug discovery.Unfortunately, at present also not as the effective serpin of anti-HCV agent.

And present known HCV does not also produce gratifying anti-HCV agent or therapeutical agent.The method of the treatment HCV disease of unique foundation is an interferon therapy.Yet Interferon, rabbit has significant side effects (people such as Janssen, 1994; Renault and Hoofnagle, 1989) [Janssen, H.L.A. wait people's " with the relevant suicide of alpha-interferon treatment chronic viral hepatitis " J.Hepatol., and 21,241-243 page or leaf (1994)]; Renault, P.F. and Hoofnagle, J.H., " alpha-interferon side effect.Hepatopathy symposial, 9,273-277. (1989)] and only in 25% case, produces and alleviate [Weiland, O. " interferon therapy in the chronic hepatitis C infection ", FEMS Microbiol.Rev., 14,279-288 page or leaf (1994)] for a long time.And the prospect of effective anti-HCV vaccine remains uncertain.

Therefore, need more effective anti-HCV therapeutical agent.This inhibitor has as proteinase inhibitor, particularly as serpin, more especially as the treatment potentiality of HCV NS3 proteinase inhibitor.Especially, this compound can be used as antiviral agent, particularly as anti-HCV agent.

The invention provides as proteinase inhibitor, particularly as serpin with more especially as the compound of HCV NS3 proteinase inhibitor, and medicinal derivative.These compounds can be separately or with immunomodulator such as α-,-β-or gamma-interferon; Other antiviral agent such as ribavirin and amantadine; Other hepatitis C protease inhibitors; HCV other target inhibitor in life cycle comprises that helicase, polysaccharase, metalloprotease or internal ribosome enter; Or its mixture share.

The present invention also provides the method for arrestin enzyme, particularly serine protease and HCV NS3 proteolytic enzyme.

The present invention also provides the pharmaceutical composition that comprises The compounds of this invention, and comprise other immunomodulator such as α-,-β-or gamma-interferon; Other antiviral agent such as ribavirin and amantadine; Other hepatitis C protease inhibitors; HCV other target inhibitor in life cycle comprises that helicase, polysaccharase, metalloprotease or internal ribosome enter; Or the multi-component combination of its mixture.The present invention also provides the method for utilizing The compounds of this invention and other related compound to suppress HCV.

In order to more fully understand the present invention described herein, elaborate specification sheets below.In this specification sheets; use following abbreviation: specify dummy suffix notation reagent or segment Abu aminobutyric acid Ac ethanoyl AcOH acetate Bn benzyl Boc tert-butoxycarbonyl Bz benzoyl Cbz carbonyl benzyloxy (carbobenzyloxy) CDI carbonyl dimidazoles DCE 1; 2-ethylene dichloride DCM methylene dichloride DIEA sec.-propyl ethamine DMA N,N-DIMETHYLACETAMIDE DMAP methylamino pyridine DMF dimethyl formamide DPPA diphenylphosphine acyl azide DMSO methyl-sulphoxide Et ethyl EtOAc ethyl acetate FMOC 9-fluorenyl methoxy carbonyl HbtU neighbour-benzotriazole base-N; N; N ', N '-tetramethyl-urea

(tetramethyluronium) HOBt N-hydroxybenzotriazole HPLC high performance liquid chromatography Me methyl MS mass spectrum NMP 1-METHYLPYRROLIDONE ND undetermined Pip piperidines Prz piperazine PyBrop bromo-three-pyrrolidino phosphorus hexafluorophosphate Pyr pyridine THF oxolane TFA trifluoroacetic acid TFE trifluoroethanol Tol toluene

This paper uses following term:

Unless carry out opposite statement, term as used herein " SO ₂-" and " S (O) ₂-" be meant sulfone or sulfone derivatives (promptly two additional groups are connected on the S), and be not the finger sulfite.

Term " replacement " is meant with the one or more hydrogen in the substituting group replacement known structure that is selected from special groups.When replacing an above hydrogen with the substituting group that is selected from identical special groups, the substituting group in each position can be identical or different.

Term as used herein " amino " is meant trivalent nitrogen, it can be connect a C atom or can replace by 1-2 alkyl.

Term " alkyl " or " alkane " use separately or use the aliphatic hydrocarbon groups that refers to that all straight or branched is saturated with any other term no matter is, wherein include the carbon atom of given number or when not specifying number, preferably comprise 1-10 and more preferably comprise 1-5 carbon atom.The example of alkyl includes but not limited to methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl-, sec-butyl, the tertiary butyl, amyl group, isopentyl, n-hexyl etc.

Term " alkenyl " or " alkene " use separately or use list or the polyunsaturated aliphatic hydrocarbon groups that all refers to straight or branched with any other term no matter is, wherein include the carbon atom of given number or when not specifying number, preferably comprise 2-10 and more preferably comprise 2-5 carbon atom.The example of alkenyl includes but not limited to vinyl, E-and Z-propenyl, E-and Z-isobutenyl, E-and Z-pentenyl, E-and Z-hexenyl, E, E-, E, Z-, Z, E-and Z, Z-hexadienyl etc.

Term " alkynyl " or " alkynes " use separately or use list or the polyunsaturated aliphatic hydrocarbon groups that all refers to straight or branched with any other term no matter is, wherein include the carbon atom of given number or when not specifying number, preferably comprise 2-10 and more preferably comprise 2-5 carbon atom, wherein at least one unsaturated fatty hydrocarbons group contains triple bond.The example of alkynyl includes but not limited to ethynyl, proyl, isobutyl alkynyl, pentynyl, hexin base, hexene alkynyl (hexenynyl) etc.

Term " aryl " uses separately or uses the carbon-ring aromatic group that all refers to contain the particular carbon atom number with any other term no matter be, and can be uncondensed or with 1-3 cycloalkyl, aromatic, heterocyclic or heteroaromatic ring condensed are for example with the benzene condensed.Preferred aryl groups has 6-14 carbon atom, more preferably 6-10 carbon atom.The example of aryl includes but not limited to phenyl, naphthyl, anthryl etc.

Term " carbocyclic ring " uses separately or uses with any other term all to refer to stable non-aromatic 3-8 unit carbon ring group no matter be, this group can be saturated, monounsaturated or polyunsaturated, and can be uncondensed or with 1-3 cycloalkyl, aromatic, heterocyclic or heteroaromatic ring condensed are for example with the benzene condensed.Carbocyclic ring can attached on the inner carbon atom to form any rock steady structure.

Term " cycloalkyl " or " naphthenic hydrocarbon " use separately or use with any other term all to refer to the stable saturated carbon ring group of non-aromatic 3-8 unit no matter be, this group can be uncondensed or with 1-3 cycloalkyl, aromatic, heterocyclic or heteroaromatic ring condensed are for example with the benzene condensed.Carbocyclic ring can be attached to the inside carbon atom of any formation rock steady structure.Preferably, carbocyclic ring has 5-6 carbon atom.The example of carbon ring group includes but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, suberyl, cyclopentenyl, cyclohexenyl, 1,2-indane, naphthane etc.

Term " cycloalkenyl group " or " cycloolefin " use separately or use with any other term all to refer to the stable cyclic hydrocarbon cyclic group that contains at least one end ring carbon-carbon double bond no matter be.Carbocyclic ring can ring-type carbon atom attached to any formation rock steady structure on.When not specifying carbon atom number, the cycloolefin group preferably has 5-7 carbon atom.The example of cycloolefin group includes but not limited to cyclopentenyl, cyclohexenyl, cyclopentadienyl, indenyl etc.

Term " ring alkylidene group " uses separately or uses with any other term all to refer to the stable cyclic hydrocarbon cyclic group that contains the outer carbon-carbon double bond of at least one ring no matter be, this cyclic hydrocarbon ring can be uncondensed or with 1-3 cycloalkyl, aromatic, heterocyclic or heteroaromatic ring condensed are for example with the benzene condensed.Carbocyclic ring can ring-type carbon atom attached to any formation rock steady structure on.When not specifying carbon atom number, the ring alkylene group preferably has 5-7 carbon atom.The example of ring alkylidene group includes but not limited to encircle pentylidene, cyclohexylene, ring inferior pentenyl etc.

The technological operation personnel can be appreciated that some group can or press aryl classification by naphthenic hydrocarbon.The example of this group comprises 1,2-indanyl and tetralyl.

Term " monocycle " or " monocyclic " are no matter be to use separately or use with any other term all to refer to 5-7 person's ring system, unless definition is arranged in this article.

Term " two ring " or " bicyclic " are no matter be to use separately or use with any other term all to refer to 6-11 person's ring system, unless definition is arranged in this article.

Term " three ring " or " trinucleated " are no matter be to use separately or use with any other term all to refer to 11-15 person's ring system, unless definition is arranged in this article.

Term " heterocyclic radical " or " heterocycle " no matter be use separately or use all with any other term refer to (unless definition is arranged in this article) stable 5-to 15-person singly, two or tricyclic heterocyclic, it be saturated or part undersaturated, but not aromatic, and can be uncondensed or with 1-3 cycloalkyl, aromatic, heterocyclic or heteroaromatic ring condensed are for example with the benzene condensed.Each heterocycle is made up of one or more carbon atoms and 1-4 heteroatoms that is selected from nitrogen, oxygen and sulphur.Term used herein " nitrogen and sulfur heteroatom " comprises the nitrogen and the sulphur of any oxidised form, and any basic nitrogen of quaternized form.Heterocycle can inside carbon atom or heteroatoms attached to any formation rock steady structure on.

Above defined preferred heterocycle comprises as imidazolidyl, draw oxazolidone base (indazolinolyl), the perhydro-pyridazinyl, pyrrolinyl, pyrrolidyl, piperidyl, pyrazolinyl, piperazinyl, base, thio-morpholinyl, β-Ka quinoline base, thiazolidyl, the thio-morpholinyl sulfone, the oxo-piperidine alkyl, the oxo-pyrrolidine base, oxo azatropylidene base, azatropylidene base (azepinyl), the furazan base, THP trtrahydropyranyl, tetrahydrofuran base, oxa-thiol group (oxathiolyl), dimercapto (dithiolyl), tetrahydrochysene thiophenyl alkyl dioxin, dioxolanyl, tetrahydrofuran (THF) and tetrahydrofuran base, tetrahydropyrans and tetrahydrofuran base, tetrahydropyrans and dihydrofuran base, dihydro pyranyl, the dihydrofuran base, dihydrofuran and tetrahydrofuran base, dihydropyrane and tetrahydrofuran base, tetramethylene sulfide sulfuryl (sulfolanyl) etc.

Term " heteroaryl " and " heteroaromatic " use separately or use the 3-that all refers to stable aromatics to 7-person's monocyclic heterocycles with any other term no matter be, and be uncondensed or with 1-3 cycloalkyl, aromatic, heterocyclic or heteroaromatic ring condensed are for example with the benzene condensed.Each hetero-aromatic ring is made up of one or more carbon atoms and 1-4 heteroatoms that is selected from nitrogen, oxygen and sulphur.Term as used herein " nitrogen and sulfur heteroatom " comprises the nitrogen and the sulphur of any oxidised form, and any basic nitrogen of quaternized form.Heterocycle can inside carbon atom or heteroatoms attached to any formation rock steady structure on.

Preferred hetero-aromatic ring defined above comprises as benzimidazolyl-, imidazolyl, quinolyl, isoquinolyl, indyl, indazolyl, pyridazine alkyl (pyridazyl), pyridyl, pyrryl, pyrazolyl, pyrazinyl, quinoxalinyl (quinoxolyl), pyranyl, pyrimidyl, pyridazinyl, furyl, thienyl, triazolyl, thiazolyl, tetrazyl, benzofuryl, oxazolyl, benzoxazolyl, isoxazolyl, isothiazolyl, thiadiazolyl group, thienyl etc.

Term " halogen " refers to group fluorine, chlorine, bromine or iodine.Preferred halogen group is fluorine and chlorine.

In chemical formula, this paper uses bracket to represent 1) have more than one and same atoms or group bonded atom or group; Or 2) fulcrum in the chain (that is, open group before the bracket or atom directly with open bracket group or atom afterwards and combine).The example of first kind of usage is " N (R ¹) ₂" two R of expression ¹Combine with nitrogen-atoms.The example of second kind of usage is " C (O) R ¹" expression Sauerstoffatom and R ¹Be attached on the carbon atom, shown in the following array structure formula:

This paper employed " B " expression boron atom.

The invention provides useful as protease inhibitors, serpin particularly is especially as the compound of HCV NS3 proteinase inhibitor.Like this, they worked by the life cycle of disturbing HCV virus and other to depend on the virus of serine protease propagation.So these compounds can be used as antiviral agent.

Therefore, in an implementation route, the invention provides the formula I compound:

Wherein: G ¹Be sulfydryl, hydroxyl, thiomethyl, alkenyl, alkynyl group, trifluoromethyl, C _1-2Alkoxyl group, C _1-2Alkylthio or C _1-3Alkyl, wherein C _1-3Alkyl can be unsubstituted or by sulfydryl, hydroxyl, thiomethyl, alkenyl, alkynyl group, trifluoromethyl, C _1-2Alkoxyl group or C _1-2Alkylthio replaces.

W ¹For Or

G ²Be alkyl; aryl; aralkyl or one; two or tricyclic heterocyclic, they can be unsubstituted or by alkyl; alkenyl; alkynyl group; aralkyl; alkoxyl group; alkenyloxy; aryloxy; heterocyclic radical; Heterocyclylalkyl; aralkoxy; the heterocycle alkoxyl group; oxo; hydroxyl; amino; alkanoylamino; alkoxycarbonyl amino; urea groups; carboxyl; the heterocyclic oxy group alkyl; aryloxy alkyl; the heterocyclic radical carbonyl; aroyl; aryl sulfonyl; the heterocyclic radical alkylsulfonyl; the heterocyclic radical sulfonamido; Arenesulfonyl amino; the aralkyl sulfonamido; the heterocyclic radical alkyloyl; carboxyalkyl; the carboxamido alkyl; alkanesulfonyl; sulfonamido; halogen; cyano group or haloalkyl replace.

G ⁴Be alkyl, alkenyl, alkynyl group, cycloalkyl, cycloalkylalkyl, cycloalkyl alkenyl, aryl, aralkyl, arylalkenyl, heterocyclic radical, heterocyclic radical alkyl, heterocyclic radical alkenyl, hydroxyalkyl, alkoxyalkyl, alkyl-thio-alkyl, aryl alkylthio or heterocyclic radical alkylthio.

Each Q ¹Be hydroxyl, alkoxyl group or aryloxy, perhaps each Q ¹Form 5-7 person's ring for Sauerstoffatom and with the boron that they connected, wherein annular atoms is carbon, nitrogen or oxygen.

U is hydrogen, G ⁹-C (O)-, G ⁹-SO ₂-, G ⁹-C (O)-C (O)-, (G ⁹) ₂-N-C (O)-C (O)-, (G ⁹) ₂-N-SO ₂-, (G ⁹) ₂N-C (O)-or G ⁹-O-C (O)-.

G ⁹Be hydrogen, alkyl, carboxyalkyl, alkenyl, aryl, aralkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl group, heterocyclic radical, heterocyclic radical alkyl, perhaps for unsubstituted or be selected from the heterocyclic radical alkenyl that alkyl, alkenyl, aralkyl, alkoxyl group, alkenyloxy, aryloxy, heterocyclic radical, carboxyalkyl, carboxamido alkyl, alkyl sulphonyl or sulfonamido replace by 1-3; Perhaps two G ⁹Base forms the nitrogenous monocycle of 4-10 person or two ring fillings or the unsaturated loop systems of part with the nitrogen-atoms that they connected, and 1-2 the atom that wherein forms ring is that the atom of N, S or O and other formation ring is C; Wherein loop systems is unsubstituted or is selected from alkyl, alkenyl, aralkyl, alkoxyl group, alkenyloxy, aryloxy, aralkoxy, heterocyclic radical, ketone group, hydroxyl, amino, alkanoylamino, carboxyl, carboxyalkyl, carboxamido alkyl, alkylsulfonyl or sulfonamido replaces by one or two.

E ⁴Be key;

Or

Wherein:

G ¹³Be cycloalkylalkyl, aralkyl, heterocyclic radical alkyl, sweet-smelling alkoxy alkyl, heterocyclic radical alkoxyalkyl, alkylthio-alkyl aryl or heterocyclic radical alkylthio alkyl, they are unsubstituted or are replaced by 1-2 alkyl, alkenyl, aralkyl, alkoxyl group, alkenyloxy, aryloxy, aralkoxy, heterocyclic radical, oxygen, hydroxyl, amino, alkanoylamino, carboxyl, carboxyalkyl, carboxamido alkyl, alkylsulfonyl or sulfonamido.

G ¹⁴For hydrogen, alkyl, alkenyl, hydroxyl, alkoxyl group or-CH ₂-G ⁸, wherein, G ⁸Be aryl, aralkyl, carbocylic radical or heterocyclic radical, wherein the loop section of aryl, aralkyl or heterocyclic radical can be unsubstituted or be replaced by the group that 1-3 is selected from alkyl, alkenyl, aralkyl, alkoxyl group, alkenyloxy, aryloxy, heterocyclic radical, Heterocyclylalkyl, aralkoxy, heterocyclic radical alkoxyl group, oxo, hydroxyl, amino, alkanoylamino, alkoxycarbonyl amido, urea groups, carboxyl, carboxyalkyl, carboxyamino alkyl, alkyl sulphonyl, sulfonamido, halogen, cyano group or haloalkyl; Or

E ⁴For

G ¹³And G ¹⁴Form nitrogenous heterocycle with their institute's bonded atoms (being respectively carbon and nitrogen) with 4-7 person, this heterocycle can not conform to be had or contains 1-2 other heteroatoms, wherein the ring system that is produced be uncondensed or unite with the second cycle line that other carbocyclic ring or heterocyclic fused formation contain 7-11 atom; And wherein monocycle or two rings can not be substituted or are selected from oxygen, hydroxyl, alkyl, alkenyl, aryl, aralkyl, alkyl, alkenyloxy aryloxy, aralkoxy, halogen or nitro by 1-2 and replace.

Each Q ³It is halogen, nitro, cyano group, alkyl, alkenyl, aralkyl, alkoxyl group, alkenyloxy, aryloxy, aralkoxy, heterocyclic radical, the heterocyclic radical alkyl, hydroxyl, amino, alkylamino, alkanoylamino, carboxyl, carboxyalkyl, the carboxamido alkyl, alkyl sulphonyl, aryl sulfonyl, the aralkyl alkylsulfonyl, alkyl sulfonyl amino, Arenesulfonyl amino or aralkyl sulfonamido, wherein any alkyl, alkenyl, aryl or heterocyclic group all can not replace or be selected from ketone by 1-3, hydroxyl, nitro, cyano group, halogen, amino, alkyl, alkoxyl group or alkylthio replace; Q wherein ³When not combining, can combine with any commutable atom with specific atoms.

Q ⁴Be alkyl independently; cycloalkyl; aryl; aralkyl; heterocyclic radical; the heterocyclic radical alkyl; alkyloyl; aryl carbonyl; aromatic alkyl carbonyl; alkoxy carbonyl; aryloxycarbonyl; aromatic alkoxy carbonyl; alkyl sulphonyl; aryl sulfonyl; the aralkyl alkylsulfonyl; alkyl amino-carbonyl; aromatic yl aminocarbonyl; the arylalkylamino carbonyl, wherein any described alkyl; cycloalkyl; aryl; aralkyl; heterocyclic radical group alternative is by one or more ketone groups that are independently selected from; hydroxyl; nitro; cyano group; halogen; amino; alkyl; the group of alkoxyl group or alkylthio replaces.

Q ⁵Be aryl or aromatic heterocycle, wherein:

Aryl or aromatic heterocycle are have 5-14 atom monocyclic, bicyclic or tricyclic, and can selectivity be selected from hydroxyl, nitro, cyano group, halogen, amino, alkyl, alkoxyl group, alkyloyl, alkylamino or alkylthio replacement by 1-3.

E ⁵For key or

G wherein ¹⁵Be alkyl, alkenyl, cycloalkylalkyl, aralkyl, heterocyclic radical alkyl, carboxyalkyl or carboxamido alkyl; wherein, the ring of any aralkyl or heterocyclic radical alkyl can be unsubstituted or be replaced by 1-2 alkyl, alkenyl, aralkyl, alkoxyl group, alkenyloxy, aryloxy, heterocyclic radical, oxygen, hydroxyl, amino, alkanoylamino, carboxyl, carboxyalkyl, carboxamido alkyl, alkylsulfonyl or sulfonamido.

E ⁶For key or Wherein, G ¹⁶Be hydrogen, alkyl, alkenyl, aralkyl or cycloalkylalkyl; E ⁷For key or

Wherein, G ¹⁷For unsubstituted or by the alkyl of carboxyl substituted; Wherein preferably, alkyl is C _1-3Alkyl.

E ⁸For key or Wherein, G ¹⁸For unsubstituted or by the alkyl of carboxyl substituted; Wherein preferably, alkyl is C _1-3Alkyl.

Each Z ¹Be O or H independently ₂, prerequisite is in giving compound, to be no more than 2 Z ¹Base is H ₂

Preferred formula I compound for those wherein at least one substituting group for as the compound of giving a definition:

G ¹For vinyl, ethynyl ,-CH ₃,-CF ₃,-CH ₂CH ₃,-CH ₂CF ₃,-SCH ₃,-SH ,-CH ₂SH or-CH ₂OH;

G ¹³Be C _3-6Branched-chain alkyl or G ¹³And G ¹⁴Has 4-7 member's nitrogen heterocyclic ring system with atom (being respectively carbon and the nitrogen) formation that they connected, this ring can not conform to or contain 1-2 other heteroatoms, and wherein monocycle or second cycle line system can be unsubstituted or be replaced by 1 or 2 group that is selected from oxygen, hydroxyl, alkyl, alkenyl, aryl, aralkyl, alkyl, alkenyloxy, aryloxy, aralkoxy, halogen or nitro; And

Z ¹Be O.

Preferred formula I compound is those wherein G ¹For-SH ,-CH ₂SH ,-CF ₃Or-CF ₂CF ₃Compound.

Most preferred formula I compound is those wherein G ¹For-SH or-CF ₃Compound.

According to another embodiment, the invention provides the formula II compound:

In these compounds:

W is: Or

M is 0 or 1.

Each R ¹Be hydroxyl, alkoxyl group or aryloxy, perhaps each R ¹Form 5-7 person's ring for Sauerstoffatom and with the boron that they connected, wherein annular atoms is carbon, nitrogen or oxygen.

Each R ²Be hydrogen, alkyl, alkenyl, aryl, aralkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl group, cycloalkenyl alkyl, heterocyclic radical, heterocyclic radical alkyl, heterocyclic radical alkenyl, heteroaryl or heteroaralkyl or two R that are connected on the identical nitrogen-atoms independently ²Base forms 5-7 person's monocyclic heterocycles system with nitrogen-atoms; Wherein, arbitrary R ²Carbon atom can be unsubstituted or be replaced by J.

J is alkyl, aryl, aralkyl, alkoxyl group, aryloxy, aralkoxy, cycloalkyl, cycloalkyloxy, heterocyclic radical, heterocyclic oxy group, Heterocyclylalkyl, ketone group, hydroxyl, amino, alkylamino, alkanoylamino, aroylamino, aralkyl amido, carboxyl, carboxyalkyl, carboxamido alkyl, halogen, cyano group, nitro, formyl radical, acyl group, alkylsulfonyl or sulfonamido and can is unsubstituted or by 1-3 J ¹Base replaces.

J ¹Be alkyl, aryl, aralkyl, alkoxyl group, aryloxy, heterocyclic radical, heterocyclic oxy group, ketone group, hydroxyl, amino, alkanoylamino, aroylamino, carboxyl, carboxyalkyl, carboxamido alkyl, halogen, cyano group, nitro, formyl radical, alkylsulfonyl or sulfonamido.

L is alkyl, alkenyl or alkynyl group, wherein be connected to any hydrogen on the carbon atom and can be unsubstituted or replace, and wherein to be connected to any hydrogen on any terminal carbon or halogen atom can be unsubstituted or replaced by sulfydryl or hydroxyl by halogen.

A ¹Be key,

Or

R ⁴For alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, carboxyalkyl or, carboxamido alkyl and can be unsubstituted or replace by 1-3 J base.

R ⁵And R ⁶Be hydrogen, alkyl, alkenyl, aryl, aralkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl group, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl independently, and can be unsubstituted or replace by 1-3 J base.

X be key ,-C (H) (R ⁷)-,-O-,-S-or-N (R ⁸)-.

R ⁷Be hydrogen, alkyl, alkenyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl, and can be unsubstituted or replace by 1-3 J base.

R ⁸For hydrogen, alkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, aralkanoyl, heterocycle alkyloyl (heteroanoyl), assorted aralkanoyl ,-C (O) R ¹⁴,-SO ₂R ¹⁴Or carboxamido, and can be unsubstituted or replace by 1-3 J base; Perhaps R ⁸Form nitrogenous monocycle or second cycle line system unsubstituted or that replace by 1-3 J with Z with the atom that they were connected.

R ¹⁴Be alkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl.

Y be key ,-CH ₂-,-C (O)-,-C (O) C (O)-,-S (O)-,-S (O) ₂-or-S (O) (NR ⁷)-, be R wherein ⁷As above definition.

Z be alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl ,-OR ²Or-N (R ²) ₂, wherein, any carbon atom can be unsubstituted or be replaced by J, wherein R ²As above definition.

A ²For key or

R ⁹For alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, carboxyalkyl or carboxamido alkyl and can be unsubstituted or replace by 1-3 J base.

M is alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl and can is unsubstituted or is replaced by 1-3 J base that wherein the carbon atom of any alkyl can be replaced by heteroatoms.

V be key ,-CH ₂-,-C (H) (R ¹¹)-,-O-,-S-or-N (R ¹¹)-.

R ¹¹Be hydrogen or C _1-3Alkyl.

K be key ,-O-,-S-,-C (O)-,-S (O)-,-S (O) ₂-or-S (O) (NR ¹¹)-, be R wherein ¹¹As mentioned above.

T is-R ¹²,-alkyl-R ¹²,-alkenyl-R ¹²,-alkynyl group-R ¹²,-OR ¹²,-N (R ¹²) ₂,-C (O) R ¹²,-C (=NO alkyl) R ¹², or

Each R ¹²Be hydrogen, aryl, heteroaryl, cycloalkyl, heterocyclic radical, cycloalkyl, ring alkylidene group or heterocycle alkylidene group, and can be unsubstituted or replace, perhaps first R by 1-3 J base ¹²With second R ¹²Form monocycle or second cycle line system unsubstituted or that replace by 1-3 J base with the nitrogen-atoms that they connected.

R ¹⁰For alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl, carboxyalkyl or carboxamido alkyl and can be unsubstituted or replace by 1-3 J base.

R ¹⁵Be alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, carboxyalkyl or carboxamido alkyl, and can be unsubstituted or replace by 1-3 J; And

R ¹⁶Be hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclic radical.

Preferably, W is

Or

More preferably, W is Or

Most preferably, W is

Wherein, R ²Be aralkyl; Or

Preferably, J is alkyl, alkoxyl group, aryloxy, aryl, aralkyl, aralkoxy, halogen, heteroaryl, cyano group, amino, nitro, heterocyclic radical, acyl group, carboxyl, carboxyalkyl, alkylamino, hydroxyl, heterocyclic radical alkyl, aralkanoyl amino, aroylamino, alkanoylamino, formyl radical or ketone group.

More preferably, J is the tertiary butyl, methyl, trifluoromethyl, methoxyl group, oxyethyl group, trifluoromethoxy, carboxyl, phenyl, benzyl, phenoxy group, benzyloxy, fluorine, chlorine, bromine, isoxazolyl, pyridyl, piperidyl, carboxymethyl, propyloic; Dialkyl amido, morpholinyl methyl, phenylacetylamino or amido.

Preferably, J ¹Be alkoxyl group, alkyl, halogen or aryl.

More preferably, J ¹Be C _1-3Alkoxyl group, halogen, C _1-3Alkyl or phenyl.

Preferably, L is alkyl, alkenyl, allyl group or propargyl.

More preferably, L is trihalogenmethyl, sulfydryl or the alkyl that replaced by trihalogenmethyl, sulfydryl or hydroxyl.

Preferably, R ⁴Be alkyl, aralkyl, cycloalkylalkyl or cycloalkyl.More preferably, R ⁴Be phenylalkyl or cycloalkyl.Most preferably, R ⁴Be isobutyl-, cyclohexyl alkyl or styroyl.

Preferably, R ⁵And R ⁶Respectively be hydrogen.

Preferably, X be-O-or-N (R ⁸)-.

Preferably, R ⁸Be hydrogen.

Preferably, Y is-CH ₂-,-C (O)-,-C (O) C (O)-or-S (O) ₂-.

Preferably, R ²Be H, fluorine, trifluoromethyl, alkyl, aryl, aralkyl, heteroaralkyl, heterocyclic radical or heterocyclic radical alkyl.

Preferably, Z is alkyl, aryl, aralkyl, heterocyclic radical, cycloalkyl, heteroaryl, OR ²Or N (R ²) ₂, wherein preferably, R ²Be aralkyl or alkenyl.

More preferably, Z is a phenyl, 1,4-benzodioxan base, 1, the amino benzo dioxolyl of 3-benzo dioxolyl, benzothiazolyl, naphthyl, phenmethyl, oxadiazole base, isoxazolyl, quinolyl, benzothienyl, thiazolyl, cyclohexyl, butyl, naphthyl, dioxolanyl, phenmethyl, pyridyl, morpholinyl, N-anilino, N-aminobenzothiazole, N-, N-amino naphthalenes, N-phenmethyl amine, N-aminopyridine, benzyloxy, allyloxy or styroyl, and can be do not replace or replaced by J.

Most preferably, Z is a naphthyl, 3,4-dichlorophenyl, 2-methoxycarbonyl phenyl.

Preferably, R ⁹Be alkyl.More preferably, R ⁹Be propyl group.Most preferably, R ⁹Be sec.-propyl.

Preferably, M is alkyl, heteroaryl, aryl, cycloalkylalkyl, aralkyl or alkaryl, and one of them alkyl carbon atoms is replaced by O or S.

More preferably, M is propyl group, methyl, pyridylmethyl, phenmethyl, naphthyl methyl, phenyl, imidazolyl methyl, thienyl methyl, cyclohexyl methyl, styroyl, phenmethyl sulphomethyl or benzyloxy ethyl.

Preferably, V is-N (R ¹¹)-.

Preferably, R ¹¹Be hydrogen.

Preferably, K be-C (O)-or-S (O) ₂-.

Preferably, T is-R ¹²,-alkyl-R ¹²,-alkenyl-R ¹²,-OR ¹²,-N (R ¹²) ₂,-C (=NO alkyl) R ¹², or

More preferably, T is-R ¹²With-alkyl-R ¹²

Preferably, R ¹²For aryl or heteroaryl and can be do not replace or replaced by 1-3 J group.More preferably, R ¹²Be 1-naphthyl, isoquinolyl, indyl or 2-alkoxyl group-1-naphthyl.

Preferably, R ¹⁰For by the alkyl of carboxyl substituted.More preferably, R ¹⁰For by the C of carboxyl substituted _1-3Alkyl.

Preferably, R ¹⁵For by the alkyl of carboxyl substituted.More preferably, R ¹⁵For by the C of carboxyl substituted _1-3Alkyl.

In a preferred routes of formula II, A ¹For:

And

A ²Be key.

Preferably, in this preferred route, X is O.

More preferably, Y is-CH ₂-.

Perhaps, Y be-C (O)-.

Perhaps, Y be-C (O)-and Z be-N (R ²) ₂-.

Perhaps, in this preferred route, X is-N (R ⁸)-.

More preferably, Y be-C (O)-.

Perhaps, Y is-S (O) ₂-.

Perhaps, Y be-C (O)-and Z be-N (R ²) ₂-.

Perhaps, in this preferred route, X is-N (R ⁸)-, be R wherein ⁸For-C (O) R ¹⁴Or-S (O) ₂R ¹⁴

More preferably, R ⁸For-C (O) R ¹⁴The time, Y is-C (O)-.

Perhaps, Y is-S (O) ₂-.

Perhaps, Y be-C (O)-and Z be-N (R ²) ₂-.

More preferably, R ⁸For-S (O) ₂R ¹⁴The time, Y is-C (O)-and Z be-N (R ²) ₂-.

At one of formula II compound of the present invention more preferably in the route, A ¹For:

Wherein, X be-O-and Y be-CH ₂-;

A ²For

V is-(NR ¹¹), and

K is-C (O)-.

At another of formula II compound of the present invention more preferably in the route, A ¹For: Wherein, X is that O and Y are CH ₂

A ²For

'

V is-(NR ¹¹), and

K is-S (O) ₂-.

At another of formula II compound of the present invention more preferably in the route, A ¹For: Wherein, X is that O and Y are-CH ₂-;

A ²Be key

V is-(NR ¹¹), and

K is-C (O)-.

At another of formula II compound of the present invention more preferably in the route, A ¹For:

Wherein, X is that O and Y are-CH ₂-;

A ²Be key

V is-(NR ¹¹), and

K is-S (O) ₂-.

Preferably, W is in these preferred routes:

Or

More preferably, W is

Or

Most preferably, W is R wherein ²Be aralkyl; Or

Preferably, in these preferred implementation routes, L is alkyl, alkenyl, allyl group or propargyl.

More preferably, L is trihalomethyl group, sulfydryl or the alkyl that replaced by trihalomethyl group, sulfydryl or hydroxyl.

In another preferred route of formula II, A ¹For

And

A ²Be key.Preferred group in this preferred implementation route is as indicated above.

In another preferred route of formula II, A ¹Be key.Preferred group in this preferred implementation route is as indicated above.

In another preferred route of formula II, A ¹For And

A ²For

Preferred, preferred and most preferred group in this preferred implementation route is as indicated above.

The present invention expects that the reactive site of the many NS3 of relating to proteinase inhibitor can be the native peptides mimic, therefore can be designed by natural substrate.So the preferred substituted of peptide simulation inhibitor of the present invention comprises that those and enzyme have the naturally occurring substrate of high-affinity (low Km) or the skeleton or the side chain corresponding base groups of synthetic substrate.

In another preferred implementation route of formula II, A ¹Be key.Preferred, preferred and most preferred group in this preferred implementation route is as indicated above.

Those skilled in the art can be appreciated that some specific group can classify by heterocycle or heteroaromatic, and this depends on binding site.

The compounds of this invention can close one or more unsymmetrical carbons and therefore can produce raceme and racemic mixture, single enantiomer, non-enantiomer mixture and each diastereomer.All these isomeric forms of these compounds all clearly are included in the present invention.The carbon of each steric isomer can be R or S configuration.The substituting group and the variant of the present invention's anticipation only are that those can produce the stable compound form.Term as used herein " stablize " refer to have be enough to allow the stability that is prepared and in the sufficiently long time, keep the compound of compound integrity with the purpose that is used for this paper and describes in detail (as, treatment or prophylactically use) to the Mammals administration or in the affinity chromatograph chromatography.Usually, these compounds are at 40 ℃ or be lower than this temperature, not moist and do not have to stablize for 1 week at least under the condition of other chemical reaction agent.

The compounds of this invention can use routine techniques to synthesize.Advantageously, these compounds are easy to be synthesized by the raw material that obtains easily.

Ding Yi The compounds of this invention (comprising formula I and (II) compound) comprises its pharmaceutically acceptable derivative or prodrug herein." its pharmaceutically acceptable derivative or prodrug " means the salt of any pharmacologically acceptable salt, ester, ester or other derivative of The compounds of this invention, and (directly or indirectly) The compounds of this invention can be provided when they are given acceptor.

Therefore, the present invention also provides the prodrug of The compounds of this invention, and this precursor is designed to improve biological nature as, the derivative of oral absorption, clearance rate, metabolic rate or chamber distribution character.These derivatives are known in the art.

Those skilled in the art can be appreciated that The compounds of this invention can be modified to improve biological selectivity characteristic by additional suitable functional group.This modification is well known in the art, and comprise increase enter the biological chamber that will give (as, blood, lymphsystem, central nervous system) bio-osmosis, increase oral bioavailability, increase the solubleness that allows drug administration by injection, change metabolism and change drainage rate.

Term " protection " relates to specified functional group and combines with suitable chemical group (protecting group).The suitable amino protecting group and the example of blocking group are described in T.W.Greene and P.G.M.Wuts, blocking group in the organic synthesis, second edition, John Wiley and Sons (1991); L.Fieser and M.Fieser are used for the Fieser and Fieser ' the s reagent of organic synthesis, John Wiley and Sons (1994); L.Paquette edits Encyclopedia ofReagents for Organic Synthesis, exemplifies in John Wiley and Sons (1995) and employed in the present invention some specific compound.

Particularly advantageous derivative and precursor be those these compounds are given Mammals (as, be easier to absorb by the orally give compound and enter blood) time increase the The compounds of this invention bioavailability, have more favourable clearance rate or metabolic patterns, perhaps those compare with parent compound strengthen parent compound discharge into biological chamber (as, brain or lymphsystem) derivative.Preferred prodrug comprises that strengthening group water-soluble or that strengthen through goldbeater's skin transport activity material is attached to formula I and (II) structural derivative.

The The compounds of this invention pharmacologically acceptable salt comprises by pharmaceutically acceptable inorganic or organic bronsted lowry acids and bases bronsted lowry derived compounds.The example of the salt of suitable acid comprises acetate, adipate, alginate, big aspartate, benzoate, benzene sulfonate, hydrosulfate, butyrates, Citrate trianion, camphorate, camsilate, cipionate, digluconate, dodecyl sulfate, esilate, formate, fumarate, the glucoheptose hydrochlorate, glycerophosphate, oxyacetate, Hemisulphate, enanthate, hexanoate, hydrochloride, hydrobromate, hydriodate, the 2-isethionate, lactic acid salt, maleate, malonate, mesylate, the 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmitate, pectinic acid salt, persulphate, 3-phenylpropionic acid salt, phosphoric acid salt, picrate, Pivalate, propionic salt, salicylate, succinate, vitriol, tartrate, thiocyanate-, tosylate and undecylate.Other acid, can be used for preparing as obtaining the useful salt of The compounds of this invention intermediate and the salt of pharmaceutically acceptable acid addition thereof although itself be not pharmaceutically useful as oxalic acid.

By suitable alkali deutero-salt comprise basic metal (as, sodium and potassium), alkaline-earth metal (as magnesium), ammonium and N-(C _1-4Alkyl) ₄ ^-Salt.The present invention also comprises the quaternized thing of any basic nitrogen compound disclosed herein.Water or the soluble or dispersible products of oil can be by this quaternized the acquisitions.

Usually, obtain formula I and (II) compound by the described method of embodiment 1-8.Yet, it will be understood by those skilled in the art that synthetic route as herein described is not all method that is used for comprising the extensive list that can synthesize the application's retouch and claimed compound thus.For a person skilled in the art, other method is conspicuous.In addition, various synthesis steps mentioned above can change to obtain required compound in proper order to it.

Without being limited by theory, we think, The compounds of this invention or by covalent linkage or by non covalent bond and HCV NS3 proteolytic enzyme and other serine stretch protein enzyme interacting suppresses this enzyme ability natural or the synthetic substrate of splitting.Non-covalent interaction is favourable, and they provide big relatively inhibition specificity and do not suppress other unwanted target, for example L-Cysteine HCL Anhydrous.Therefore, when giving Mammals with these compounds, they have than passing through the bigger therapeutic index of the interactional proteolytic enzyme of covalent linkage, and they can interact with the proteolytic enzyme of relative broad range and cause unwanted toxic action.On the contrary, it is favourable interacting by covalent linkage, and they provide bigger restraining effect, the specificity problem that allows to give lower dosage and therefore improve any of shortage.

The new compound of the present invention is the inhibitor of good proteolytic enzyme, particularly serine protease and HCVNS3 proteolytic enzyme.Therefore, these compounds can target and arrestin enzyme, serine protease, especially HCV NS3 proteolytic enzyme especially.Therefore, these compound viral interferences comprise the life cycle of HCV and therefore are used as antiviral agent.Can measure restraining effect by the method for the whole bag of tricks such as embodiment 11.

Term " antiviral agent " is meant that having virus suppresses active compound or medicine.This inhibitor comprises reverse transcriptase inhibitors (comprising nucleosides and the sweet analogue of non-nuclear) and proteinase inhibitor.Preferably, proteinase inhibitor is the HCV proteinase inhibitor.

Term as used herein " treatment " is meant the symptom that alleviates patient's specified disease or improves the provable measuring method relevant with certain specified disease.Term as used herein " patient " is meant that Mammals comprises the people.

Therefore, according to another embodiment, the invention provides pharmaceutical composition, it comprises formula I or (II) or its pharmacologically acceptable salt; Other antiviral agent, its be selected from but be not restricted to immunomodulator such as α-, β-or gamma-interferon; Other antiviral agent such as ribavirin and amantadine; Other HCV proteinase inhibitor; The inhibitor of other target HCV life cycle comprises helicase, polysaccharase, metalloprotease; Or their mixture and any pharmaceutical carrier, auxiliary material or vehicle.Another embodiment provides the composition that comprises formula I or (II) or its pharmacologically acceptable salt and pharmaceutically acceptable carrier, auxiliary material or vehicle.Said composition can not comprise or comprise other be selected from immunomodulator such as α-,-β-or gamma-interferon; Other antiviral agent such as ribavirin; Other HCV proteinase inhibitor; HCV helicase inhibitor or their mixture.

Term " pharmaceutically acceptable carrier or auxiliary material " is meant the carrier or the auxiliary material that can give the patient with The compounds of this invention, and they do not destroy the pharmacologically active of The compounds of this invention, and is nontoxic when giving with the dosage that is enough to discharge the therapeutic dose compound.

Spendable pharmaceutical carrier in pharmaceutical composition of the present invention, auxiliary material and vehicle include but not limited to, ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, automatic emulsified drug delivery system (SEDDS) is as the d alpha-tocopherol, the cetomacrogol 1000 succinate, with tensio-active agent such as tween or other the similar polymkeric substance release matrix that pharmaceutical dosage forms uses, serum protein such as human serum albumin, buffer reagent such as phosphoric acid salt, glycine, Sorbic Acid, potassium sorbate, the mixture of saturated vegetable fatty acid partial glycerol ester, water, salt or ionogen such as vitriolate of tartar, Sodium phosphate dibasic, potassium hydrogen phosphate, sodium-chlor, zinc salt, colloid silica, Magnesium Trisilicate, polyvinylpyrrolidone, Mierocrystalline cellulose sample material, polyoxyethylene glycol, Xylo-Mucine, polyacrylic ester, wax, polyethylene-polyoxypropylene block polymer, polyoxyethylene glycol and lanolin.Preferably, also can use cyclodextrin as " α-, β-and γ-Huan Hujing or the chemical process derivative such as hydroxyalkyl cyclodextrin of modifying, comprise that 2-and 3-hydroxypropyl-beta-cyclodextrin or other solubilising derivative promote the release of formula I or (II) compound.

Pharmaceutical composition of the present invention can or be implanted the reservoir administration by oral, non-enteron aisle, suction spraying, part, rectum, nose, cheek, vagina.Preferred oral administration or pass through drug administration by injection.Pharmaceutical composition of the present invention can comprise the nontoxic pharmaceutically acceptable carrier of any routine, auxiliary material or vehicle.In some cases, the PH that can regulate preparation with pharmaceutically acceptable acid, alkali or buffer reagent with promote the stability of the compound of being prepared or its releasing pattern.That the non-enteron aisle of term as used herein comprises is subcutaneous, in the intracutaneous, intravenously, intramuscular, intraarticular, synovial membrane chamber, in the sheath, intralesional and intracranial injection or infusion techn.

Pharmaceutical composition can be sterilization injection form, for example sterile water for injection or oily suspensions.Can utilize suitable dispersion agent or wetting agent (as tween 80) and suspension agent to prepare this suspension according to technology known in the art.The sterilization injection also can be thinner or sterilizing injecting solution in the solvent or the suspension of using at nontoxic non-enteron aisle, as the solution in 1,3 butylene glycol.Spendable suitable carrier or solvent are mannitol, water, Ringer's solution and isotonic sodium chlorrde solution.In addition, use aseptic fixed oil as solvent or suspension medium usually.For this reason, can use the fixed oil of any gentleness to comprise synthetic list and two glyceryl ester.Lipid acid such as oleic acid and glyceride derivative thereof, and natural acceptable oil such as sweet oil or Viscotrol C, particularly their polyoxy ethylization form can be used in the injection.These oily solutions or suspension also can comprise those or the similar alcohol described in long-chain alcohol thinner or dispersion agent such as the Pharmacopeia Helvetica (Ph.Helv.), or carboxymethyl cellulose or similarly, the dispersion agent such as emulsifying agent and/or the suspension agent that in the preparation of pharmaceutically acceptable dosage form, use usually.In order to prepare, also can use other normally used tensio-active agent such as tween or sapn and/or other emulsifying agent or bioavailability promotor similar, that in producing pharmaceutically acceptable solid, liquid or other dosage form, use usually.

Pharmaceutical composition of the present invention can be with any suitable oral dosage form by orally give, and described suitable oral dosage form includes but not limited to, capsule, tablet and aqueous suspension agent and solution.In the tablet that orally uses, normally used carrier comprises lactose and W-Gum.Typically, also can add lubricant such as Magnesium Stearate.Concerning with the capsule form oral administration, employed thinner comprises lactose and exsiccant W-Gum.When by the orally give waterborne suspension, chemical composition is mixed with lubricant and suspension agent.If desired, can add some sweeting agents and/or correctives and/or tinting material.

Pharmaceutical composition of the present invention also can give with the suppository form that is used for rectal administration.Can by with The compounds of this invention with suitable, at room temperature for solid but in rectum for liquid in case discharge active ingredient, nonirritant excipient mixes and prepares these compositions.This material includes but not limited to: theobroma oil, beeswax and polyoxyethylene glycol.

When needed treatment related to the zone that enters easily by topical application or organ, the topical application present composition was useful especially.For local application in skin, pharmaceutical composition should be mixed with suitable, comprise the ointment that suspends or be dissolved in active ingredient in the carrier.Include but not limited at the employed carrier of the preparation of topical application The compounds of this invention: mineral oil, whiteruss (liquid petroleum), white vaseline (white petroleum), propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.Perhaps, pharmaceutical composition can be mixed with suitable washing lotion or the creme that suspends or be dissolved in active compound in the carrier that contain.Suitable carrier includes but not limited to mineral oil, Stearinsaeure sorbitol ester, Spheron MD 30/70 60, hexadecanol ester type waxes, hexadecanol (cetearyl alcohol), 2-Standamul G, phenylcarbinol and water.Pharmaceutical composition of the present invention also can be applied topically to the lower end enteron aisle with the rectal suppository form or with suitable enema forms.The topical transdermal patch is also contained in the present invention.

Pharmaceutical composition of the present invention can come administration by nasal aerosol or inhalation.Prepare this based composition according to technique known in the medicine formulation art, and can make salt brine solution, can use absorption enhancer, fluorocarbons and/or other solvating agent known in the art or the dispersion agent of phenylcarbinol or other suitable sanitas, enhancing bioavailability.

Preventing and treating antiviral, can use about 0.01 when particularly treating separately in the disease of whose anti-HCV mediation and arrive between about 100mg/kg body weight/day, preferably at about 0.5 dosage level to the protease inhibitor compound described herein between about 75mg/kg body weight/day.Usually, pharmaceutical composition of the present invention is will every day about 1-5 time or carry out continuous infusion.This medication can be used for chronic or acute treatment.The amount with the active ingredient that produces unit dosage form of mixing with solid support material depends on the host that treated and specific administering mode.General preparation contains 5% to about 95% the active compound (w/w) of having an appointment.Preferably, this class preparation contains 20% to about 80% the active compound of having an appointment.

When composition of the present invention contains the mixture of formula I or (II) compound and one or more other treatments or preventive, compound and other medicines should be with in the single therapy routes between about 10-100%, more preferably the bio-occlusion pharmaceutical quantities between about 10-80% exists.

In the implementation route, the present composition contains other immunomodulator.The example of other immunomodulator include but not limited to α-, β-and δ-Interferon, rabbit.

In another implementation route, pharmaceutical composition of the present invention can contain antiviral agent in addition.The example of antiviral agent comprises ribavirin and amantadine.

In another implementation route, pharmaceutical composition of the present invention can contain other HCV proteinase inhibitor in addition.

In the implementation route, pharmaceutical composition of the present invention can contain the inhibitor of other target in the HCV life cycle in addition, as helicase, polysaccharase or metalloprotease again.

In order to improve patient's symptom, if desired, can give The compounds of this invention, composition or the mixture of maintenance dose.Subsequently, be that function is reduced to the level that keeps improving symptom with dosage and/or frequency with the symptom, when symptom has been relieved to desired level, should stop treatment.Yet, can carry out long-term intermittent therapy to the patient based on any recurrence of disease symptoms.

One skilled in the art will recognize that, can require than lower or higher dosage mentioned above.The concrete dosage of any given patient and treatment route will depend on various factors, comprise the activity, age, body weight of employed particular compound, total healthy state, sex, diet, administration time, drainage rate, medicine unite uses, the seriousness that infects and stage, to the disposal of patient infection and the judgement for the treatment of the doctor.

When these compound or pharmaceutically acceptable salt thereofs and pharmaceutically acceptable carrier preparation, resulting composition can give Mammals in the body, as the people, suppresses serine protease, particularly HCV NS3 proteolytic enzyme or treatment or prophylaxis of viral infections, particularly HCV virus infection.This treatment also can use The compounds of this invention and other active groups is incompatible finishes, and these promoting agents include but not limited to: immunomodulator, as α-, β-and δ-Interferon, rabbit; Other antiviral agent such as ribavirin and amantadine; Other HCV NS3 proteinase inhibitor; Other target is in the inhibitor of HCV life cycle, as composition in helicase, polysaccharase, metalloprotease or the rrna or their mixture.These other promoting agents can mix with The compounds of this invention to produce unit dosage form.In addition, these other promoting agents part of also can be used as the multidose form gives Mammals separately.

Therefore, another implementation route of the present invention is by giving the method that formula I or (II) compound suppress the Mammals serine protease, and wherein the substituting group definition is the same.Preferably, serine protease is HCV NS3.

In another implementation route, the invention provides and suppress Mammals HCV or the active method of HCV NS3, comprise the step that gives described Mammals formula I or (II) compound, wherein the substituting group definition is the same.

In another implementation route, the invention provides the method that reduces the Mammals serine protease, comprise the step of the mixture that gives any pharmaceutical composition of described Mammals and drug combination, wherein the substituting group definition is the same.If pharmaceutical composition only contains The compounds of this invention as activeconstituents, this method can comprise in addition and gives described Mammals and be selected from immunomodulator, antiviral agent, HCV proteinase inhibitor or other target in the step of the promoting agent of the inhibitor of HCV life cycle.This other promoting agent can be before giving the HCV inhibitor combination, simultaneously or give Mammals afterwards.

In another preferred implementation route, these methods can be used for suppressing mammiferous virus replication.This method is used for the treatment of or prevents for example virus disease, as HCV.If pharmaceutical composition only contains The compounds of this invention as activeconstituents, this method can comprise in addition and gives described Mammals and be selected from immunomodulator, antiviral agent, HCV proteinase inhibitor or other target in the step of the promoting agent of the inhibitor of HCV life cycle.This other live agent can be before giving the HCV inhibitor combination, simultaneously or give Mammals afterwards.

Compound as herein described also can be used as laboratory reagent.The compounds of this invention also can be used to handle or prevent the virus pollution material also therefore to reduce the laboratory or contact the healthcare givers of this material or the danger of patient's virus infection.These materials include but not limited to biomaterial, as blood tissues etc.; Surgery instrument and clothes; Laboratory apparatus and clothes; And blood collecting equipment and material.

In order to more fully understand the present invention, the following example is described.These embodiment constitute qualification to the scope of the invention never in any form.General material and method

The general synthetic method of preparation The compounds of this invention is provided among the embodiment 1.Preparation The compounds of this invention (comprising compound 1-198) method more specifically is provided among the embodiment 2-9.

The HPLC data of reporting in table 1-7 are represented with solvent gradient, residence time and purity.In each method, use deionized water.

Obtain all compounds gauged (M+H) by subsidiary material laser desorption mass spectrograph (Kratos MALDI I) or electronic spraying mass spectrograph (MICROMASS Quatro II) ⁺And/or (M+Na) ⁺Molion.

Embodiment 1

Synthetic middle each seed amino acid that uses of peptide of the present invention or peptide mimics is commercially available, for example, buys from Sigma chemical Company or Bachem Feinchemikalien AQ (Switzerland).The amino acid that can not buy can make (" non-natural and rarely have an amino acid whose kinetic resolution: by the enantioselective hydrolysis of the catalytic N-acylamino acid of Acylase I " by known route of synthesis, Chenault, H.K. etc., JACS 111,6354-6364 (1989) reaches and wherein quotes as proof; " by strecker reaction pair β-γ-unsaturated amino acid whose synthesizing ", Greenlee, W.J., organic chemistry magazine 49,2632-2634 (1984); " the nearest stereospecific synthesis method of beta-amino acids ", Cole, D.Tetrahedron 50:9517 (1994); " ring-type alpha-imino acidifying ", Mauger, A.B; Volume 4 of " amino acid, peptide and protein chemistry and biochemistry ", Weinstein, B.editor, Marcel Dekker (1977); " latest developments in the synthetic and reaction of the piperidines of replacement ", Org.Prep.Procedure Int.24,585-621 (1992), all these documents all are incorporated herein for reference).

Some compounds of formula I or (II) can be synthesized by the known method of amino acid by peptide field and the synthetic field of organic chemistry.This synthetic example is at Bodanszky and Bodanszky, and " peptide is synthetic to be put into practice ", Springer-Verlag, Berlin, Germany (1984), " peptide ", Gross and Meinhofer edit; AcademicPress, 1979, I-III volume and Stewart, J.M. and Young, J.D., " solid-phase peptide is synthetic, second edition ", Pierce Chemical Company, Rockford, IL (1984); With " recent development that produces of molecular diversity ", Moos, W.H., Green, G.D. and Pavia, M.R. " the pharmaceutical chemistry annual report, 28 volumes " the 315-324 page or leaf; Bristol, J.A.. edits; AcademicPress, San Diego, CA (1993) has carried out general description, and all these documents all are incorporated herein for reference.

Typically; liquid phase for peptide is synthetic; protected by urethane such as Boc, Cbz, Fmoc or Alloc by the amino acid whose α-amine of coupling, activate the free carboxyl by in the presence of catalyzer such as HOBT, HOAT, HOSu or DMAP, reacting simultaneously with carbodiimide such as DCC, EDC and DIC.Other method also is suitable, as by horse back Acibenzolar, carboxylic acid halides, enzyme activated amino acid with comprise the acid anhydride of phosphorus reagent such as BOP, Py-BOP, N-carboxyl-acid anhydride, symmetrical anhydride, blended carbonic anhydride, carbon-phosphine and carbon-phosphoric anhydride mediate and carry out.Form after the peptide; remove protecting group by the method described in the above listed reference, as by hydrogenation in the presence of palladium, platinum or rhodium catalyst, be used in liquefied ammonia sodium, hydrochloric acid, hydrofluoric acid, Hydrogen bromide, formic acid, trifluoromethanesulfonic acid or trifluoroacetic acid, secondary amine, fluorion, trimethyl silyl halogenide comprises bromide and iodide or alkaline purification.Use technology as indicated above, include but not limited to Advanced Chemtech 357 FBS and 496MOS by being purchased instrument; Tecan CombiTec and Applied Biosystem 433A finish automatic building-up process.The concrete application and the equivalent method thereof of these methods are apparent to those skilled in the art, and this depends on the purpose compound.The improvement of chemical process and the selection of instrument are all within the common experimenter's in this area technical scope.

Embodiment 2

Compound 1-26 (table 1) prepares by the method for describing in the synthetic route 1.Route 1 301-306's is synthetic

Steps A, 301 synthetic: with 4-methyldiphenyl methylamine resin (1.05mmol/g, 20.0g) be placed in the sintered glass funnel and ((2 * 75ml) solution washings are also last with dimethyl formamide (4 * 75ml) washings for the dimethyl formamide of 3 * 75ml), 10% (v/v) diisopropylethylamine (DIEA) with dimethyl formamide.The dimethyl formamide of q.s is added in this resin so that obtain slurry, add 300 (8.0g then, 20.8mmol, according to A.M.Murphy et.al. JACS, 114,3156-3157 (1992) is from (2S) 2-(tert-butoxycarbonyl amino)-butyraldehyde preparation), I-hydroxybenzotriazole hydrate (HOBTH ₂O; 3.22g, 21.0mmol), neighbour-benzotriazole-N, N, N, N '-tetramethyl-urea hexafluorophosphate (HBTU; 8.0g, 21.0mmol), and DIEA (11.0ml, 63mmol).This mixture is at room temperature used bracket formula vibrator (wrist arm shaker) shaken overnight.(3 * 75ml) wash by the suction strainer separation and with dimethyl formamide on sintered glass funnel with resin.Then, by (unreacted amido protection (capped) is got up in 2 * 50ml) directly reactions in funnel (10 minutes/washing) with resin and 20% (v/v) diacetyl oxide/dimethyl formamide.Before vacuum-drying is spent the night, with resin with dimethyl formamide (3 * 75ml) and methylene dichloride (3 * 75ml) washings obtain 300a (26.3g, 81% productive rate).

By following method, the t-Boc protecting group is removed from 300a with Advanced ChemTech 396 polypeptide synthesizers.By (resin 300a is expanded in 3 * 1ml) washings, then by with 50% (v/v) TFA/ methylene dichloride (1.0ml) washing 10 minutes (under vibration), uses fresh reagent (1ml) to wash again and the t-Boc protecting group is disconnected in 30 minutes with methylene dichloride.(3 * 1ml), then (3 * 1ml), (2 * 1ml), (3 * 1ml) washings obtain resin 301 to use N-Methyl pyrrolidone at last to use 10%DIEA/ dimethyl formamide (v/v) then with DMF with methylene dichloride with resin then.

Step B, 303 synthetic: utilize Advanced ChemTech 396 polypeptide synthesizers, (0.05mmol) prepares this compound from resin 301.The solution in N-Methyl pyrrolidone (0.5ml) with resin 301 usefulness 0.4M302 and 0.4M HOBT, 0.4M HBTU in N-Methyl pyrrolidone (0.5ml) solution and 1.6M DIEA in N-Methyl pyrrolidone (0.35ml) the solution acidylate and reactant at room temperature vibrated 4 hours.Repeat this linked reaction.(3 * 1ml) washings, then (3 * 1ml) washings obtain resin 303 with methylene dichloride with dimethyl formamide with resin then.

Step C, 305 synthetic: utilize Advanced ChemTech 396 polypeptide synthesizers to realize the synthetic of resin-bonded compound.(3 * 1ml) washings then by with 50% (v/v) TFA/ methylene dichloride (1.0mi) washing 10 minutes (under vibration), are used fresh reagent (1ml) to wash again and the t-Boc protecting group were disconnected in 30 minutes with resin 303 usefulness methylene dichloride.(3 * 1ml), then (3 * 1ml), (2 * 1ml), (3 * 1ml) washings obtain resin 304 to use N-Methyl pyrrolidone at last to use 10%DIEA/ dimethyl formamide (v/v) then with DMF with methylene dichloride with resin then.Then with this resin with 0.4M Fmoc-Xie Ansuan and the solution of 0.4M HOBT in N-Methyl pyrrolidone (0.5ml), 0.4M HBTU in N-Methyl pyrrolidone (0.5ml) solution and 1.6M DIEA in N-Methyl pyrrolidone (0.35ml) the solution acidylate and reactant at room temperature vibrated 4 hours.Repeat this linked reaction.This automatization cycle comprises (1), (3 * 1ml) wash with methylene dichloride with resin; (2) (the solution deprotection in 3 * 1ml) 3 minutes is then with fresh reagent deprotection 10 minutes at dimethyl formamide with 25% (v/v) piperidines; (3) before as above carrying out coupling, with resin with dimethyl formamide (3 * 1ml) and N-Methyl pyrrolidone (3 * 1ml) wash.In the method, Fmoc-Xie Ansuan and pyrazine-2-carboxylic acid is by in the coupling.

Step D, 306 synthetic: before disconnecting, (3 * 1ml) washed vacuum-drying then with 1: 1 methylene chloride with resin.By at room temperature using 95%TFA/5%H ₂(v/v 1.5ml) handled 30 minutes or by at room temperature using tetrahydrofuran (THF)/30% formalin/1N HCl9: 1: 1 (v: v: v) handled 1 hour, aldehyde is disconnected from resin O.With resin with lytic reagent (1ml) washing after, the white powder that the filtrate water dilution that merges and lyophilize are obtained crude product 306.By partly preparing RP-HPLC, (15 μ, 30 * 300mm) purifying are with the linear acetonitrile gradient that contains 0.1%TFA (v/v), with 20/ minute speed wash-out 45 minutes with Waters DeltaPak 300 A C18 posts with compound.Cut and lyophilize that collection contains desired product obtain 306.

Embodiment 3

As preparation compound 27-29 (table 1) as described in the synthetic route 2.Route 2

Steps A, synthetic 301: the method for seeing synthetic route 1 steps A.

Step B, synthetic 308: by (3 * 50ml) washings, (6.0g, 0.65mmol/g 3.9mmol) expand in sintered glass funnel with resin 301 with methylene dichloride.By with 50% (v/v) TFA/ methylene dichloride (50ml) washing 10 minutes (stirring discontinuously), use fresh reagent (50ml) washing 30 minutes more then, the Boc protecting group is disconnected.(3 * 50ml), (2 * 50ml), (2 * 50ml), (3 * 50ml) wash 10%DIEA/ dimethyl formamide (v/v) dimethyl formamide to use N-Methyl pyrrolidone at last with resin 303 usefulness methylene dichloride then.After resin transfer is in the 100ml flask, add N-Methyl pyrrolidone and obtain slurry, then add 307 (2.83g, 8.0mmol), HOBTH ₂O (1.22g, 8.0mmol), HBTU (3.03g, 8.0mmol) and DIEA (4.2ml, 24mmol).This mixture is at room temperature used bracket formula vibrator (wrist arm shaker) shaken overnight.Described in 301, resin handled and, obtain 308 (6.86g, quantitative productive rates) with the dimethyl formamide solution protection (capping) of 20% (v/v) diacetyl oxide.

Step C, synthetic 309: utilize Tecan CombiTec synthesizer to prepare this compound from resin 308 (0.15mmol).(3 * 2ml) washings with dimethyl formamide (2.5ml) the solution deprotection of 25% (v/v) piperidines 5 minutes, are followed with fresh reagent (2ml) deprotection 20 minutes with dimethyl formamide with resin 308 (0.076mmol).Using 0.4M Fmoc-Xie Ansuan and the solution of 0.4MHOBT in N-Methyl pyrrolidone (0.8ml); 0.4M before the solution and the solution acidylate of 1.6M DIEA in N-Methyl pyrrolidone (0.6ml) of HBTU in N-Methyl pyrrolidone (0.8ml), with resin with dimethyl formamide (3 * 2.5ml) and N-Methyl pyrrolidone (3 * 2.5ml) washings were also at room temperature vibrated reactant 8 hours.Repeat this linked reaction.Repeat deprotection and coupling process so that add second Xie Ansuan base and the last pyrazine-2-carboxylic acid group of adding.(3 * 2.5ml) washings obtain resin 309 with methylene dichloride with resin then.

Step D, synthetic 310: in resin 309, add 1: 1 pyridine/methylene dichloride (v/v) (1ml), the 0.8M dimethyl aminopyridine in methylene dichloride (0.2ml) solution and 0.2M C-COCl in methylene dichloride (1.5ml) solution and reactant at room temperature vibrated 8 hours.Repeat acylation reaction.With resin with methylene dichloride (3 * 2.5ml), dimethyl formamide (3 * 2.5ml), methylene dichloride (3 * 2.5ml) washings, and (3 * 2.5ml) washings obtain resin 310 to use 1: 1 methylene chloride at last.

Step e, synthetic 311: before disconnection, (3 * 1ml) washed vacuum-drying then with 1: 1 methylene chloride with resin.By at room temperature using tetrahydrofuran (THF)/formalin/acetate/1N HCl 5: 1: 1: 0.1 (v: v: v: v) handled 1 hour, aldehyde is disconnected from resin.With resin with lytic reagent (1ml) washing after, the white powder that the filtrate water dilution that merges and lyophilize are obtained crude product 311.By partly preparing RP-HPLC, (15 μ, 30 * 300mm) purifying are with the linear acetonitrile gradient that contains 0.1%TFA (v/v), with 20/ minute speed wash-out 45 minutes with Waters DeltaPak300 A C18 post with compound.Cut and lyophilize that collection contains desired product obtain 311.

Embodiment 4

As preparation compound 30-56 (table 1) as described in the synthetic route 3.Route 3

Steps A, synthetic 301: the method for seeing synthetic route 1 steps A.

Step B, synthetic 308: the method for seeing synthetic route 2 step B.

Step C, synthetic 312: utilize Tecan CombiTec synthesizer to prepare this compound from resin 308 (0.15mmol).(3 * 2.5ml) wash and are suspended in the toluene (1.0ml) with resin 308 usefulness toluene.In this suspension, add 0.8M R ₃The toluene of δ-isocyanic ester (1.0ml) solution then adds toluene (1.0ml) solution of 0.8M DIEA, perhaps adds 0.8M R in this suspension ₃The toluene of δ-carboxylic acid and 0.8MEIDA (1.0ml) solution then adds toluene (1ml) solution of 0.8M diphenyl phosphoryl azide.Reactant was vibrated 8 hours down at 55 ℃.Then with resin with toluene (3 * 2.5ml) and dimethyl formamide (4 * 2.5ml) washings obtain resin 312.

Step D, synthetic 313: the method for seeing synthetic route 2 step D.

Step e, synthetic 314: the method for seeing synthetic route 2 step e.

Embodiment 5

As preparation compound 57-70 (table 1) as described in the synthetic route 4.Route 4

Steps A, synthetic 301: the method for seeing synthetic route 1 steps A.

Step B, synthetic 316: utilize Advanced ChemTech 396 polypeptide synthesizers, (0.05mmol) prepares this compound from resin 301.The solution in N-Methyl pyrrolidone (0.5ml) with resin 301 usefulness 0.4M 315 and 0.4MHOBT, 0.4M HBTU in N-Methyl pyrrolidone (0.5ml) solution and 1.6M DIEA in N-Methyl pyrrolidone (0.35ml) the solution acidylate and reactant at room temperature vibrated 4 hours.Repeat this linked reaction.(3 * 1ml) washings are then with methylene dichloride (3 * 1ml) washings with dimethyl formamide with resin then.By under eddy current, handled 10 minutes with 50% (v/v) TFA/ methylene dichloride (1.0ml), use fresh reagent (1.0ml) to handle then and the Boc protecting group disconnected in 30 minutes.Then with resin with methylene dichloride (3 * 1.0ml), dimethyl formamide (2 * 1.0ml), 10%DIEA/ dimethyl formamide (v/v) (2 * 1,0ml), dimethyl formamide (3 * 1.0ml) washings and last (3 * 1.0ml) wash and obtain 316 with methylene dichloride.

Step C, synthetic 317a: with resin 316 0.4M Z-CO ₂H and the 0.4M HOBT solution in N-Methyl pyrrolidone (0.5ml), 0.4M HBTU in N-Methyl pyrrolidone (0.5ml) solution and 1.6M DIEA in N-Methyl pyrrolidone (0.35ml) the solution acidylate and reactant at room temperature vibrated 4 hours.Repeat this linked reaction.(3 * 1ml) washings obtain resin 317a with dimethyl formamide with resin then.

Step C, synthetic 317b: at room temperature, with solution and 1.6M DIEA the solution acidylate in N-Methyl pyrrolidone (0.35ml) 2 hour of resin 316 usefulness 0.5M Z-COCl in dimethyl formamide (1ml).Repeat this acidylate step.(3 * 2.5ml) washings obtain resin 317b with dimethyl formamide with resin.

Step C, synthetic 317c: at room temperature, resin 316 and methylene dichloride (0.5ml) solution of 1.0M Z-SULPHURYL CHLORIDE and methylene dichloride (0.60ml) solution one of 1M pyridine were reacted 4 hours.Repeat this reaction.(3 * 1.0ml) washings, (3 * 1.0ml) washings obtain resin 317c to use dimethyl formamide then with methylene dichloride with resin.

Step C, synthetic 317d: at room temperature dimethyl formamide (1.2ml) solution one of resin 316 with 0.5M Z-isocyanic ester was reacted 8 hours.Repeat this reaction.(3 * 1.0ml) washings obtain resin 317d with dimethyl formamide with resin.

Step C, synthetic 317e: at room temperature, in the presence of acetate (0.1ml) and sodium cyanoborohydride (200mg), with resin 316 and 0.5M Z-CHO reaction.Repeat this reaction.(3 * 1.0ml) washings obtain 317e with dimethyl formamide with resin.

Step D, synthetic 318: utilize Advanced ChemTech 396 polypeptide synthesizers to realize the synthetic of resin-bonded compound.Utilize that the automatization cycle adds the Fmoc-Xie Ansuan described in the synthetic route 1 step C, then add another Fmoc-Xie Ansuan and the last pyrazine-2-carboxylic acid that adds.

Step e, synthetic 319: the method for seeing synthetic route 2 step e.

Embodiment 6

As preparation compound 81-100 (table 3 and 4) as described in the synthetic route 5.Route 5

Steps A, synthetic 301: the method for seeing synthetic route 1 steps A.

Step B, synthetic 320: utilize Advanced ChemTech 396 polypeptide synthesizers, (0.05mmol) begins to come the synthetic resins binding compounds from resin 165.Utilize that the automatization cycle adds Fmoc-A described in the synthetic route 1 step C ¹, then add Fmoc-Xie Ansuan and the terminal Fmoc-amino acid of last adding.As mentioned above, with 25% piperidines/dimethyl formamide (v: v) remove the Fmoc base and obtain resin 166.

Step C, synthetic 321a: with resin 320 0.4M T-CO ₂H and the 0.4M HOBT solution in N-Methyl pyrrolidone (0.5ml), 0.4M HBTU in N-Methyl pyrrolidone (0.5ml) solution and 1.6M DIEA in N-Methyl pyrrolidone (0.35ml) the solution acidylate and reactant at room temperature vibrated 4 hours.Repeat this linked reaction.Then with the resin dimethyl formamide (3 * 1ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1ml) washings obtain resin 321a.

Step C, synthetic 321b: at room temperature, with solution and 1.6M DIEA the solution acidylate in N-Methyl pyrrolidone (0.35ml) 2 hour of resin 320 usefulness 0.5MT-COCl in dimethyl formamide (1ml).Repeat this acidylate step.With resin with dimethyl formamide (3 * 1ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1ml) washings obtain resin 321b.

Step C, synthetic 321c: at room temperature, resin 320 and methylene dichloride (0.5ml) solution of 1.0M T-SULPHURYL CHLORIDE and methylene dichloride (0.60ml) solution one of 1M pyridine were reacted 4 hours.Repeat this reaction.With resin with methylene dichloride (3 * 1.0ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1ml) washings obtain resin 303c.

Step C, synthetic 321d: at room temperature, dimethyl formamide (1.2ml) solution one of resin 320 with 0.5M T-isocyanic ester was reacted 8 hours.Repeat this reaction.With resin with dimethyl formamide (3 * 1.0ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1ml) washings obtain resin 321d.

Step D, synthetic 322: by at room temperature using 95%TFA/5%H ₂(v/v 1.5ml) handled 45 minutes O, and aldehyde is disconnected and whole deprotection from resin.After resin usefulness fresh lysate reagent (1ml) washing, the filtrate that merges is added to 1: 1 ether of refrigerative: separate with decant by centrifuging in the pentane (12ml) and with resulting precipitation.With resulting resolution of precipitate at 10% acetonitrile/90%H ₂Among the O/0.1%TFA (15ml) and lyophilize obtain the white powder of crude product 322.By partly preparing RP-HPLC, (15 μ, 30 * 300mm) purifying are with the linear acetonitrile gradient that contains 0.1%TFA (v/v), with 20/ minute speed wash-out 45 minutes with Waters DeltaPak 300 A C18 posts with compound.Cut and lyophilize that collection contains desired product obtain 322.

Embodiment 7

As preparation compound 143-197 (table 6) as described in the synthetic route 6.Route 6

Steps A, synthetic 301: the method for seeing synthetic route 1 steps A.

Step B, synthetic 326: utilize Applied Biosystem Model 433A peptide synthesizer, (0.50mmol) prepares this compound from resin 301.Utilize the standard coupling cycle, make coupling agent, in N-Methyl pyrrolidone, N with HBTU and HOBt ^αThe amino-acid sequence of-Fmoc-protection is added to and obtains resin 326 on the resin 301.

Step C, synthetic 327a: utilize Advanced ChemTech 396 polypeptide synthesizers to realize that this is synthetic.With resin 326 (0.05mmol) with dimethyl formamide (1ml) the solution deprotection of 25% (v/v) piperidines 3 minutes, then with fresh reagent (1ml) deprotection 10 minutes.With resin with dimethyl formamide (3 * 1ml) and the N-dimethyl pyrrolidone (3 * 1ml) washing.With resin 0.4M T-CO ₂H and the 0.4M HOBT solution in N-Methyl pyrrolidone (0.5ml), 0.4M HBTU in N-Methyl pyrrolidone (0.5ml) solution and 1.6M DIEA in N-Methyl pyrrolidone (0.35ml) the solution acidylate and reactant at room temperature vibrated 4 hours.Repeat this linked reaction.Then with resin with dimethyl formamide (3 * 1ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1ml) washings obtain 327a.

Step C, synthetic 327b: utilize Advanced ChemTech 396 polypeptide synthesizers to realize that this is synthetic.With resin 326 (0.05mmol) with dimethyl formamide (1ml) the solution deprotection of 25% (v/v) piperidines 3 minutes, then with fresh reagent (1ml) deprotection 10 minutes.With resin with dimethyl formamide (3 * 1ml) and the N-dimethyl pyrrolidone (3 * 1ml) washing.At room temperature, with resin with N-Methyl pyrrolidone (0.35ml) the solution acidylate of dimethyl formamide (1ml) solution of 0.5M T-COCl and 1.6MDIEA 2 hours.Repeat this acidylate step.Then with resin with dimethyl formamide (3 * 1ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1ml) washings obtain 327b.

Step C, synthetic 327c: utilize Advanced ChemTech 396 polypeptide synthesizers to realize that this is synthetic.With resin 326 (0.05mmol) with dimethyl formamide (1ml) the solution deprotection of 25% (v/v) piperidines 3 minutes, then with fresh reagent (1ml) deprotection 10 minutes.With resin with dimethyl formamide (3 * 1ml) and methylene dichloride (3 * 1ml) wash.At room temperature, with methylene dichloride (0.60ml) solution reaction of methylene dichloride (0.5ml) solution of resin and 1.0M T-SULPHURYL CHLORIDE and 1M pyridine 4 hours.Repeat this reaction.Then with resin with dimethyl formamide (3 * 1.0ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1.0ml) washings obtain 327c.

Step C, synthetic 327d: utilize Advanced ChemTech 396 polypeptide synthesizers to realize that this is synthetic.With resin 326 (0.05mmol) with dimethyl formamide (1ml) the solution deprotection of 25% (v/v) piperidines 3 minutes, then with fresh reagent (1ml) deprotection 10 minutes.(3 * 1ml) wash with dimethyl formamide with resin.At room temperature, with dimethyl formamide (1.2ml) solution reaction of resin and 0.5M T-isocyanic ester 8 hours.Then with resin with dimethyl formamide (3 * 1.0ml), methylene dichloride (3 * 1.0ml) and 1: 1 methylene chloride (v/v) (3 * 1.0ml) washings obtain 327d.

Step D, synthetic 328: the method for seeing synthetic route 1 step D.

Embodiment 8

As preparation compound 79-123 (table 2,3 and 4) as described in the synthetic route 7.Route 7

Steps A, synthetic 330: at room temperature and DIEA (0.47ml, 2.7mmol) exist down, in methylene dichloride, with 2-chloro-chlorine trityl resin (2.2mmol/g, 1.69g) and 329 (0.385g, 1.1mmol is according to S.L.Harbeson et.al.J.Med.Chem., 37,2918 (1994) preparations) reaction is 1 hour.To react quenching and resin will be separated on sintered glass funnel and (3 * 25ml) wash with methylene dichloride by adding methyl alcohol by suction strainer.Resin vacuum-drying spent the night obtain 330 (1.92g, 0.49meq/g).

Step B, synthetic 322: utilize Applied Biosystems Model 433A peptide synthesizer and resin 330 (0.74mmol) to synthesize this resin-bonded compound.Utilize the automatization cycle described in the synthetic route 1 step C to add Fmoc-A ¹, then add Fmoc-A ²And Fmoc-A ³Use 25% piperidines/dimethyl formamide (v/v) to remove the Fmoc base as mentioned above and obtain resin 332.

Step C, synthetic 333: before disconnecting, (3 * 1ml) washed vacuum-drying then with 1: 1 methylene chloride with resin.By at room temperature using acetate: trifluoroethanol: methylene dichloride (1: 1: 3) is handled and skin was disconnected from resin in 1 hour.With resin with washed with dichloromethane after, the filtrate vacuum concentration that merges is obtained the white powder (0.48g, 76%) of crude product 333.

Step D, synthetic 335: (0.05g 0.058mmol) is dissolved in the N,N-DIMETHYLACETAMIDE (1ml) and to wherein adding DIEA (0.17mmol), suitable amine (0.20mmol) and PyBrop (0.12mmol) with compound 333.This reactant was stirred 2 hours down at 70 ℃.Then this reactant is diluted to H ₂Among the O (8ml), follow the centrifugal precipitation that obtains, should precipitate vacuum-drying and obtain crude product 334, this crude product direct oxidation is obtained compound 335.Crude product 334 is dissolved in the N-Methyl pyrrolidone (3ml) and at room temperature, (110mg, 0.26mmol) reaction is spent the night with Dess-Martin periodinane.(w: v) sodium thiosulfate solution (5ml) is added in this reactant and is adding H with saturated sodium bicarbonate aqueous solution (5ml) and 10% ₂O (40ml) stirs before.By centrifugal with precipitate and separate and with this solid vacuum-drying.When needs, by at room temperature using 1: 1 trifluoroacetic acid: methylene dichloride is handled and was removed sour unstable protection base in 30 minutes.The solvent vacuum removed and with the crude product compound by partly preparing RP-HPLC, (15 μ, 30 * 300mm) purifying are with the linear acetonitrile gradient that contains 0.1%TFA (v/v), with 20/ minute speed wash-out 45 minutes with WatersDeltaPak 300 A C18 posts.Cut and lyophilize that collection contains desired product obtain 335.

Embodiment 9

Peptide acid preparation compound 71-78 and 124-126 from due care.As above synthetic route 7 is described, with the peptide acid of 2-chloro-chlorine trityl resin preparation protection.Utilize the peptide coupling method of standardized solution, these peptide acid are coupled on one of following groups.The reference of these groups of preparation also is provided.

J.Oleksyzyn et.al., synthetic, 985-986 (1979)

S.Elgendy?et.al.,Tetrahedron,50,3803-3812(1994)

M.R.Angelestro?et.al.,Tetrahedron?Letters,33,3265-3268(1992)

T.T.Curran et.al., organic chemistry magazine, 58,6360-6363 (1993)

E.Edwards et.al., pharmaceutical chemistry magazine, 38,3972-3982 (1995).

When needs, described in synthetic route 7, utilize Dess Martin Periodinane that resulting product is oxidized to ketone.When needs, by at room temperature using 1: 1 trifluoroacetic acid: methylene dichloride is handled and was removed sour unstable protection base in 30 minutes.The solvent vacuum removed and with the crude product compound by partly preparing RP-HPLC, (15 μ, 30 * 300mm) purifying are with the linear acetonitrile gradient that contains 0.1%TFA (v/v), with 20/ minute speed wash-out 45 minutes with Waters DeltaPak 300 A C18 posts.Cut and lyophilize that collection contains desired product obtain the finished product 71-78 and 124-126.

Embodiment 10

By revising the general method described in the embodiment 1 is prepared compound 198.

Structure and the analytical data of table 1 compound 1-70

Structure and the analytical data of table 2 compound 71-79.

Structure and the analytical data of table 3 compound 80-88.

Structure and the analytical data of table 4 compound 89-126.

Structure and the analytical data of table 5 compound 127-142.

Structure and the analytical data of table 6 compound 143-197.

The structure of table 7 compound 198 and analytical data.

	The MS data	HPLC
			?198	(M+Na)=702.4	?10-60％B；4.2?min.； ?＞95％

Embodiment 11

Formula I or formula II compound can suppress the NS3 serine protease, and obviously, they have the treatment virus disease, comprise the clinical practice of HCV.These test predictive compounds suppress the ability of HCV in vivo.Peptide and mensuration thereof

(San Jose CA) buys peptide EDVV abuCSMSY (Abu is called aminobutyric acid), DEMEECSQHLPYI, ECTTPCSGSWLRD and EDVV AbuC-p-Nitraniline from AnaSpec Inc..

Measure peptide content purifying, the lyophilize peptide and peptide wherein and in preparation deposit peptide solution (Galbreath), use suitable value by deciding nitrogen analysis.By Robertson MicrolitLaboratories, (Madison NJ) measures pKa to Inc..

Under 30 ℃, the 25nM of use in the 100 μ L volumes that contain 50mMHEPES-KOH (pH7.8), 100mM NaCl, 20% glycerine, 5mM DTT carries out HPLC cracking mensuration to the substrate (in DMSO) of 3.0 μ M enzymes and appropriate amount, be with or without the NS4A peptide in the substrate, make final DMSO concentration be no more than 4%.Independently controlled trial proves that the DMSO of this percentage composition does not influence the activity of enzyme.By adding isopyknic 10%TFA: acetonitrile (1: 1) mixture is ended and at reversed-phase HPLC (Rainin C18 Microsorb-MV, 5mm, 4.6 * 250mm scission reaction; The 0-50% acetonitrile, 0.1%TFA@3.33% minute) use and automatic injector and diode are housed arrange Hewlett Packard 1050 instruments and measure active at 210nm and 280nm when suitable ().Collect peptide wash-out segment and identify by mass spectrum and N-terminal analysis.Further prove conclusively pulsating characteristic and concentration by credible synthetic product.(MA) Jia She Michaelis-Menten kinetics is measured the catalysis parameter for Day Computing, Cambridge to measure cracked starting velocity and use MultiFit program when＜20% substrate conversion.

Under 30 ℃, (Molecular Devices, Sunnyvale CA) carry out spectrophotometry to use the SpectraMax250 readout instrument with kinetics ability in 96 hole titer plate.Under 30 ℃ of temperature, be used for having in the same buffer that HPLC measure to use or carry out when not having NS44 EDVV AbuC-right-p-nitroanilide (5A-pNA) substrate cracking and detect pNA release at 405nm place.PH 5.5 and when above optical extinction coefficient and the pH of right-p-nitroanilide irrelevant (Tuppy, H., etc., Hoppe-Seyler ' s Z.Physiol.Chem., 329,278-288 page or leaf (1962); Raybuck and Luong, unexposed observations).In this was measured, the percentage ratio of DMSO did not surpass 4%.

Use the damping fluid that contains 50mM MES, 25Nm Tris, 25mM thanomin and 0.1M sodium-chlor of a series of ionic homeostasis intensity to measure Vmax, Km and Vmax/Km variation (Morriso with pH, J.F. and Stone, R.F. biological chemistry, 27,5499-5506 (1988)).Calculate the weight break point of logV data by the non-linear minimum area that meets following equation data.

Log v=log[Vmax/ (1+H/Ka)] [Dixon, M. and Webb, E.C. enzyme; Academic Press:New York; Vol., 138-164 page or leaf (1979)].Calculate the weight break point of logV/K data by the non-linear minimum area that meets following equation data.

Log v=log[Vmax/ (1+H/Ka+Kb/H)] [Dixon, M. and Webb, E.C. enzyme; Academic Press:New York; Vol., 138-164 page or leaf (1979)].Service routine Kinetic (BioKinLtd) all in both cases.

By meeting (Morrison, J.F.Biochim.Biophys.Acta., 185,269-286 page or leaf (1969)) the non-linear minimum area of the equation 1 described in the literary composition is by speed and [4A], and [EDVV Abuc-pNA] data are measured the kinetic constant of the bisubstrate reaction of quick equilibrium sequence.By speed with [inhibitor], [substrate] data with meet and mix the K that inhibiting equation is measured inhibitor peptides _IiAnd K _IsValue:

Speed=Vmax[s]/Km (1+[I]/K _Is)+[S] (1+[I]/K _Ii) in two processes, all use commercial programs KinetAsyst (StateCollege, PA).The non-linear minimum area of Morrison equation (Morrison, J.F.Biochim.Biophys.Acta., 185,269-286 page or leaf (the 1969)) data by meeting the competitive inhibitory effect of combining closely is by speed and [inhibitor] some calculating K i value.In this process, service routine Kinetic (BioKin Ltd).

The result is presented in the table 9.The Ki value is represented with μ M.Catalogue " A " expression＜1 μ M restraining effect; Catalogue " B " expression 1-1001 μ M restraining effect; Symbol " ND " expression is not tested compound.

91-198 Ki ( μM ) Ki ( μM ) Ki ( μM ) 1 B 42 B 83 B2 B 43 B 84 B3 B 44 B 85 B4 B 45 B 86 B5 B 46 B 87 B6 B 47 B 88 B7 B 48 B 89 B8 B 49 B 90 B9 B 50 B 91 B10 B 51 B 92 B11 B 52 B 93 B12 B 53 B 94 B13 B 54 B 95 B14 B 55 B 96 B15 B 56 C 97 B16 B 57 B 98 B17 B 58 B 99 B18 B 59 B 100 B19 B 60 C 101 A20 B 61 C 102 A21 B 62 B 103 A22 B 63 B 104 A23 B 64 B 105 A24 B 65 B 106 A25 B 66 B 107 A26 B 67 C 108 A27 B 68 C 109 B28 B 69 B 110 B29 B 70 B 111 C30 B 71 A 112 B31 B 72 B 113 B32 B 73 B 114 C33 C 74 B 115 B34 B 75 B 116 B35 B 76 C 117 B36 C 77 C 118 B37 B 78 B 119 C38 B 79 B 120 B39 B 80 A 121 C40 B 81 B 122 C41 B 82 B Ki ( μM ) Ki ( μM ) Ki ( μM ) 123 B 149 B 174 B124 B 150 B 175 B125 B 151 C 176 C126 C 152 C 177 C127 C 153 B 178 C128 B 154 B 179 B129 B 155 B 180 C130 C 156 B 181 C131 B 157 B 182 C132 B 158 B 183 B133 B 159 B 184 B134 C 160 B 185 B135 B 161 C 186 C136 B 162 B 187 C137 B 163 C 188 C138 B 164 C 189 C139 C 165 C 190 C140 B 166 C 191 C141 B 167 C 192 C142 B 168 B 193 C143 C 169 C 194 C144 C 170 C 195 B145 B 171 C 196 B146 B 172 C 197 B147 C 173 C 198 A148 C

Although we have described many implementation routes of the present invention hereinbefore, the basic design that obviously can change me is provided for other implementation route of the inventive method.So, the concrete implementation route that scope of the present invention should be determined rather than above provide with by way of example by appended here claim.

Claims (37)

1, a kind of formula II compound:

Wherein

W is:

Or

M is 0 or 1;

Each R ¹Be hydroxyl, alkoxyl group or aryloxy, perhaps each R ¹Form 5-7 person's ring for Sauerstoffatom and with the boron that they connected, wherein annular atoms is carbon, nitrogen or oxygen;

Each R ²Be hydrogen, alkyl, alkenyl, aryl, aralkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl group, cycloalkenyl alkyl, heterocyclic radical, heterocyclic radical alkyl, heterocyclic radical alkenyl, heteroaryl or heteroaralkyl or two R that are connected on the identical nitrogen-atoms independently ²Base forms 5-7 person's monocyclic heterocycles system with nitrogen-atoms; Wherein, arbitrary R ²Carbon atom can be unsubstituted or be replaced by J;

J is alkyl, aryl, aralkyl, alkoxyl group, aryloxy, aralkoxy, cycloalkyl, cycloalkyloxy, heterocyclic radical, heterocyclic oxy group, Heterocyclylalkyl, ketone group, hydroxyl, amino, alkylamino, alkanoylamino, aroylamino, aralkyl amido, carboxyl, carboxyalkyl, carboxamido alkyl, halogen, cyano group, nitro, formyl radical, acyl group, alkylsulfonyl or sulfonamido and can is unsubstituted or by 1-3 J ¹Base replaces.

J ¹Be alkyl, aryl, aralkyl, alkoxyl group, aryloxy, heterocyclic radical, heterocyclic oxy group, ketone group, hydroxyl, amino, alkanoylamino, aroylamino, carboxyl, carboxyalkyl, carboxamido alkyl, halogen, cyano group, nitro, formyl radical, alkylsulfonyl or sulfonamido;

L is alkyl, alkenyl or alkynyl group, and wherein any hydrogen can be unsubstituted or be replaced by halogen, and wherein to be connected to any hydrogen on any terminal carbon or halogen atom can be unsubstituted or replaced by sulfydryl or hydroxyl;

A ¹Be key,

Or

R ⁴For alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, carboxyalkyl or, carboxamido alkyl and can be unsubstituted or replace by 1-3 J base.

R ⁵And R ⁶Be hydrogen, alkyl, alkenyl, aryl, aralkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl group, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl independently, and can be unsubstituted or replace by 1-3 J base;

X be key ,-C (H) (R ⁷)-,-O-,-S-or-N (R ⁸)-;

R ⁷Be hydrogen, alkyl, alkenyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl, and can be unsubstituted or replace by 1-3 J base;

R ⁸For hydrogen, alkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, aralkanoyl, heterocycle alkyloyl (heteroanoyl), assorted aralkanoyl ,-C (O) R ¹⁴,-SO ₂R ¹⁴Or carboxamido, and can be unsubstituted or replace by 1-3 J base; Perhaps R ⁸Form nitrogenous monocycle or second cycle line system unsubstituted or that replace by 1-3 J with Z with the atom that they were connected;

R ¹⁴Be alkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl;

Y be key ,-CH ₂-,-C (O)-,-C (O) C (O)-,-S (O)-,-S (O) ₂-or-S (O) (NR ⁷)-, be R wherein ⁷As above definition;

Z be alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl ,-OR ²Or-N (R ²) ₂, wherein, any carbon atom can be unsubstituted or be replaced by J, wherein R ²As above definition;

A ²For key or

R ⁹For alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, carboxyalkyl or carboxamido alkyl and can be unsubstituted or replace by 1-3 J base;

M is alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl and can is unsubstituted or is replaced by 1-3 J base that wherein any alkyl carbon atoms can be replaced by heteroatoms;

V be key ,-CH ₂-,-C (H) (R ¹¹)-,-O-,-S-or-N (R ¹¹)-;

R ¹¹Be hydrogen or C _1-3Alkyl;

K be key ,-O-,-S-,-C (O)-,-S (O)-,-S (O) ₂-or-S (O) (NR ¹¹)-, be R wherein ¹¹As mentioned above;

T is-R ¹²,-alkyl-R ¹²,-alkenyl-R ¹²,-alkynyl group-R ¹²,-OR ¹²,-N (R ¹²) ₂,-C (O) R ¹²,-C (=NO alkyl) R ¹², or

Each R ¹²Be hydrogen, aryl, heteroaryl, cycloalkyl, heterocyclic radical, cycloalkyl, ring alkylidene group or heterocycle alkylidene group, and can be unsubstituted or replace, perhaps first R by 1-3 J base ¹²With second R ¹²Form monocycle or second cycle line system unsubstituted or that replace by 1-3 J base with the nitrogen-atoms that they connected;

R ¹⁰For alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl or heteroaralkyl, carboxyalkyl or carboxamido alkyl and can be unsubstituted or replace by 1-3 J base;

R ¹⁵Be alkyl, cycloalkyl, aryl, aralkyl, heterocyclic radical, heterocyclic radical alkyl, heteroaryl, heteroaralkyl, carboxyalkyl or carboxamido alkyl, and can be unsubstituted or replace by 1-3 J; And

R ¹⁶Be hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclic radical.

2, claim 1 compound, wherein A ¹For:

3, claim 2 compound, wherein R ⁵And R ⁵Be hydrogen.

4, claim 3 compound,

And R ⁹Be alkyl.

5, claim 4 compound, wherein R ⁹Be sec.-propyl.

6, claim 5 compound, wherein L is an alkyl.Alkenyl or alkynyl group, wherein any hydrogen can be unsubstituted or be replaced by halogen, and wherein to be connected to any hydrogen on any terminal carbon or halogen atom can be unsubstituted or replaced by sulfydryl or hydroxyl.

7, claim 6 compound, wherein L is trihalogenmethyl, sulfydryl or hydroxyl.

8, claim 7 compound, wherein:

X is-O-or-N (H)-; And

Y is-CH ₂-,-C (O)-or-S (O) ₂-.

9, claim 8 compound, wherein V be-N (H)-and K for-C (O)-or-S (O) ₂-.

10, claim 1 compound, wherein A ¹For:

And R ⁵And R ⁶Be hydrogen;

A ²For:

And R ⁹Be sec.-propyl;

L is an ethyl;

X is-O-or-N (H)-;

Y is-CH ₂-,-C (O)-or-S (O) ₂-;

V is-N (H)-; And

K is-C (O)-.

11, claim 10 compound, wherein M is a sec.-propyl.

12, claim 11 compound, wherein Z is aryl or heteroaryl.

13, claim 12 compound, wherein T is aryl or heteroaryl.

14, claim 13 compound, wherein T is a pyrazine.

15, claim 10 compound, wherein X be-O-and Y be-CH ₂-.

16, claim 15 compound, wherein Z is aryl or heteroaryl.

17, claim 16 compound, wherein Z is an aryl.

18, claim 10 compound, wherein M is a sec.-propyl.

19, claim 18 compound, wherein T is-R ¹²,-OR12 ,-N (R ¹²) ₂Or

20, claim 19 compound, wherein M is alkyl, heteroaralkyl, aryl, cycloalkylalkyl, aralkyl or aralkyl, one of them alkyl carbon atoms is replaced by O or S.

21, claim 20 compound, wherein said heteroatoms are S or O.

22, claim 21 compound, wherein T is aryl or heteroaryl.

23, claim 22 compound, wherein T is a pyrazine.

24, claim 3 compound, wherein

A ²Be key;

L is an ethyl;

X is-O-;

Y is-CH ₂-;

V is-N (H)-; And

K is-C (O)-or-S (O) ₂-.

25, claim 24 compound, wherein M is a sec.-propyl.

26, claim 25 compound, wherein Z is aryl or heteroaryl.

27, claim 26 compound, wherein Z is a phenyl.

28, claim 27 compound, wherein T is-R ¹²,-alkyl-R ¹²,-alkenyl-R ¹²,-OR ¹²,-N (R ¹²) ₂,-C (=NO alkyl) R ¹², or

29, claim 1 compound, wherein

A ¹For And

A ²For

30, claim 29 compound, wherein M be sec.-propyl and K for-C (O)-.

31, claim 30 compound, wherein T is-R ¹²,-alkyl-R ¹²,-alkenyl-R ¹²,-OR ¹²,-N (R ¹²) ₂,-C (=NO alkyl) R ¹², or

32, the arbitrary compound of claim 1-31, wherein W is Or

33, pharmaceutically acceptable composition comprises:

A), the claim 1-32 compound that effectively suppresses HCV proteolytic enzyme amount; With

B), Shi Yi pharmaceutical carrier.

34, the method that suppresses serine protease, it comprises and gives arbitrary compound among described patient's claim 1-32.

35, claim 34 method, wherein, described serine protease is a HCV NS3 proteolytic enzyme.

36, treatment or prevention of hepatitis C infection patient's method, it comprises and gives arbitrary compound among described patient/Mammals claim 1-32.

37, claim 36 method wherein gives described compound the patient and described compound is mixed with pharmaceutically acceptable composition with suitable pharmaceutical carrier.